The SURPASS-CVOT trial is a phase 3, randomized, double-blind cardiovascular outcomes trial that will assess tirzepatide for both non-inferiority and superiority against dulaglutide. For dulaglutide, this effect is already proven: According to the Trulicity website, the drug may be used in adults with type 2 diabetes to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors. How do I know which medication is right for me
Glutathione is one of the ovarys main protectors
Transparent Labs Hydrate is also sweetened naturally with stevia and is free from artificial sweeteners and colors
IM: Conceptualization, Supervision, Validation, Writing review & editing
It inhibits tyrosinase activity that reduces the concentration of eumelanin, responsible for skin dullness